Quest Diagnostics has introduced a new blood test aimed at assisting physicians in confirming amyloid brain pathology related to Alzheimer's disease in individuals with mild cognitive impairment (MCI) ...
Quest Diagnostics will soon begin offering a new blood-based in-vitro diagnostic test for Alzheimer’s. The disease affects nearly 7 million Americans. The Lumipulse G pTau 217/β-Amyloid 1-42 Plasma ...
In an oral presentation at the 2025 AAN Annual Meeting, Quest scientists presented data suggesting the test can accurately assess Alzheimer's disease pathology with greater than 90% sensitivity and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results